Literature DB >> 9276628

Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells.

R Sinha1, D Medina.   

Abstract

Methylselenocysteine (MSC), an organic selenium compound has significant anticarcinogenic activity against mammary tumorigenesis. Previous experiments have demonstrated that MSC and inorganic selenite inhibit mammary cell (TM6 cell line) growth through different pathways. The present investigation demonstrated that MSC arrested cells in S phase during the TM6 cell cycle, which was followed by cells entering apoptosis at 48 h. Methylselenocysteine specifically affected the cdk2 kinase activity of the TM6 cells (54% reduction) at 16 h after release from growth arrest. The cdk4 kinase activity did not change during the cell cycle, confirming that cells had passed the G1 checkpoint and had entered S phase. The amount of cyclin E associated with cdk2 was increased by MSC by the 12 h time point, thereby facilitating entry of cells into S phase. Afterwards, cyclin E and cyclin A associated with cdk2 did not change for the remainder of the cell cycle. The data demonstrate that inhibition of mammary cell growth by MSC is mediated by alterations in progression of cells through S phase. The decrease in cdk2 kinase activity is coincident with prolonged arrest in S phase. One consequence of prolonged arrest may be apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276628     DOI: 10.1093/carcin/18.8.1541

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

Review 1.  Chemopreventive mechanisms of selenium.

Authors:  G F Combs
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 2.  Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status.

Authors:  Mark C Ledesma; Brittney Jung-Hynes; Travis L Schmit; Raj Kumar; Hasan Mukhtar; Nihal Ahmad
Journal:  Mol Med       Date:  2010-09-21       Impact factor: 6.354

3.  Identification of new proteins in follicular fluid from mature human follicles by direct sample rehydration method of two-dimensional polyacrylamide gel electrophoresis.

Authors:  Han-Chul Lee; Sang-Wha Lee; Kyo Won Lee; Sook-Whan Lee; Kwang-Yul Cha; Kye Hyun Kim; Suman Lee
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

4.  Relationship between reactive oxygen species and sodium-selenite-induced DNA damage in HepG2 cells.

Authors:  Yunfeng Zou; Piye Niu; Zhiyong Gong; Jin Yang; Jing Yuan; Tangchun Wu; Xuemin Chen
Journal:  Front Med China       Date:  2007-07-01

Review 5.  Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.

Authors:  Junxuan Lü; Jinhui Zhang; Cheng Jiang; Yibin Deng; Nur Özten; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2015-11-23       Impact factor: 2.900

6.  Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.

Authors:  Junjie Luo; Zhiye Hu; Yuan Xiao; Tongxin Yang; Chune Dong; Jian Huang; Hai-Bing Zhou
Journal:  Medchemcomm       Date:  2017-05-24       Impact factor: 3.597

Review 7.  Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Authors:  Cristina W Nogueira; Nilda V Barbosa; João B T Rocha
Journal:  Arch Toxicol       Date:  2021-04-01       Impact factor: 6.168

8.  Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.

Authors:  Emmanual Unni; Dimpy Koul; Wai-Kwan Alfred Yung; Raghu Sinha
Journal:  Breast Cancer Res       Date:  2005-07-06       Impact factor: 6.466

9.  Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine.

Authors:  Emmanual Unni; Frances S Kittrell; Uma Singh; Raghu Sinha
Journal:  Breast Cancer Res       Date:  2004-07-29       Impact factor: 6.466

Review 10.  Status of selenium in prostate cancer prevention.

Authors:  G F Combs
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.